In a rush? You can use our Quick Contact Form to tell us the basic information about your case.
We are investigating Andexxa blood clot side effects cases for patients who developed a pulmonary embolism or deep vein thrombosis, causing them to be hospitalized or resulting in their death.
Here are some basic facts about these Andexxa drug injury cases seeking legal compensation:
- Andexxa (andexanet) is a treatment used when the reversal of anticoagulation is needed for life-threatening or uncontrolled bleeding in patients who are using Eliquis (apixaban) or Xarelto (rivaroxaban).
- For Andexxa drug injury cases to be successful, the patients must be using this anticoagulant reversal drug at the time of their pulmonary embolism (PE) or deep vein thrombosis (DVT) diagnosis.
- The FDA has been looking into an apparent increased rate of Andexxa blood clot side effects, which can lead to DVT and/or PE, as well as clotting-related deaths, compared with a different means to reverse anticoagulation.
- These cases would be filed as Andexxa drug injury lawsuits against AstraZeneca, the responsible pharmaceutical company.
We will continue to monitor this relatively new drug safety issue of Andexxa blood clot side effects, causing pulmonary embolism (PE) or deep vein thrombosis (DVT).
Free Case Evaluation for Andexxa Blood Clot Side Effects
We encourage you to submit a Case Evaluation Form online – it is free, confidential, and there is no obligation. Or, if you prefer, call 910-256-2971 to speak directly to attorney Tom Lamb about a possible Andexxa drug injury lawsuit. Either way, you will get Mr. Lamb’s impressions – not an intake person, a paralegal, or some other lawyer – based on his over 25 years of experience handling drug injury cases.
Most Recent Article About Andexxa Causing Blood Clots, PE, DVT
Andexxa Blood Clot Drug Injury Lawsuits
We are investigating possible Andexxa blood clot drug injury lawsuits for patients who developed a pulmonary embolism (PE) or deep vein thrombosis (DVT), or the families of those who died while using Andexxa.
To read more of this article, click below:
As background, here are our earlier posts:
- “Andexxa Blood Clots and Clotting-Related Deaths: FDA November 2024” (1/22/2024)
- “Andexxa Blood Clot Cases Before Any AstraZeneca Drug Recall” (1/6/2025)
According to this December 12, 2025, MedPage Today news report, “Anticoagulant Reversal Drug Pulled From U.S. Market“, we learned that Andexxa will be withdrawn from the US market next week, on December 22, 2025.
The pharmaceutical company responsible for Andexxa, AstraZeneca, asserts that this Andexxa recall has to do with “commercial reasons”. However, that December 2025 MedPage Today article, as we had previously, points out Andexxa blood clots that have been associated with Andexxa use:
Safety concerns arose as early as 2016’s ANNEXA-4 initial study presentation, however, when outside observers noted a signal of excess thrombotic events among the study’s [Andessa (andexanet)] users. The clotting issue became more apparent with ANNEXA-I showing more thrombotic events (14.6% vs 6.9%) and more thrombosis-related deaths (2.5% vs 0.9%) comparing [Andessa (andexanet)] versus usual care with a prothrombin complex concentrate (PCC).
Even before this December 2025 Andexxa recall in the US, we had been looking into possible Andexxa blood clot drug injury lawsuits for patients who developed a pulmonary embolism (PE) or deep vein thrombosis (DVT), causing them to be hospitalized or resulting in their death.
For those people, we encourage you to submit an Andexxa Blood Clots Case Evaluation Form online – it is free, confidential, and there is no obligation.
[Read the article in full at Drug Injury Watch]Earlier articles about Andexxa blood clot side effects:
- Andexxa Blood Clot Cases Before Any AstraZeneca Drug Recall
- Andexxa Blood Clots and Clotting-Related Deaths: FDA November 2024